|Podcasts|July 12, 2010

Podcast: CRS and Sustainability Forum: Science and Human Rights

CRS and Sustainability Forum: Science and Human Rights

Jessica Wyndham, project director of the Science and Human Rights Program of the American Association for the Advancement of Science (AAAS), discusses AAAS’s Science and Human Rights Coalition, a recently formed group within AAAS, to facilitate partnerships and communication on human rights within the scientific community and between scientific and human-rights groups.

More Podcasts

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

October 15th, 2026

Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1

Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

October 14th, 2026

FDA Rare Disease Framework Puts CMC Review in Scope

The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.

NVIDIA’s $250M compute donation backs UK agentic AI safety research relevant to GMP AI validation.

October 14th, 2026

NVIDIA’s $250M Agentic AI Safety Bet: What GMP Gains

NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.

October 14th, 2026

PharmTech AI Pulse Check: Who Owns Authorship, Oversight, and Trust in AI-Driven Evidence

Jaenisch, Muraru, and Pandey join PharmTech's Cole to discuss FDA's generative AI paper, ARPA-H's SURPASS trials, and AI accountability.

October 13th, 2026

Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC

Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.

October 13th, 2026

Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree

Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.

IoT Internet of Things, Internet network technology, digital software development, big data concept | Image Credit: ©tippapatt -stock.adobe.com

October 13th, 2026

Using Automation to Enhance Manufacturing: Building the Foundation for Pharma 4.0

This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.

October 12th, 2026

PharmTech AI Pulse Check: AI Watermark Vulnerability

PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.

Podcast: CRS and Sustainability Forum: Science and Human Rights

Related to this article

Trending on Pharmaceutical Technology

FDA Rare Disease Framework Puts CMC Review in Scope

Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree

PharmTech AI Pulse Check: AI Watermark Vulnerability

Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC

PharmTech AI Pulse Check: Who Owns Authorship, Oversight, and Trust in AI-Driven Evidence